The Potential Role of Intensity-Modulated Proton Therapy in Hepatic Carcinoma in Mitigating the Risk of Dose De-Escalation
10/12/2020
/
Publications
/
VMAT
IMPT
A cohort of 30 patients was retrospectively selected as "at-risk" of dose de-escalation due to the proximity of the target volumes to dose-limiting healthy...
Treating Hodgkin and non-Hodgkin lymphoma with proton therapy
22/12/2020
/
White Paper
/
Pencil Beam Scanning - PBS
VMAT
Proton therapy is different from photon-based radiotherapy. Because of their unique physical properties, protons have no ‘exit’ dose and very little ‘entrance’...
Cookies policy
If you continue browsing this website, you agree to the use of cookies in order to provide you with services and offers tailored to your own interests.
Manage your cookie preferences
Respect for your privacy is still a priority for us at IBA.
Functional cookies ensure that the website runs smoothly. They cannot be turned off. By setting your preferences, you can turn the use of these cookies on and off on our website, although these settings will only be valid on the device you are currently using.